
Tel-Aviv, Israel—BioLight Israeli Life Sciences Investments’ ViSci, its wholly owned subsidiary, has been informed that the FDA has granted a patent number covering the proprietary formulation of its glaucoma treatment, latanoprost, by the U.S. Patent and Trademark Office.

The patent is intended to protect, inter alia, the chemical structure of the active ingredient for the treatment. The patent is also covering the release of the active ingredient from the Eye-D subconjunctival insert and its use in treating elevated IOP in patients with glaucoma and ocular hypertension.

The patent and its registration will be in effect at least until April 2030.

ViSci holds an exclusive option from Novaer to a worldwide exclusive license for any use of the insert's proprietary technology.

Reproduction in whole or in part is prohibited.
